Literature DB >> 28987474

Expression of checkpoint molecules on myeloid-derived suppressor cells.

Marlene Ballbach1, Angelika Dannert1, Anurag Singh1, Darina M Siegmund1, Rupert Handgretinger1, Luca Piali2, Nikolaus Rieber3, Dominik Hartl4.   

Abstract

Myeloid-derived suppressor cells (MDSCs) are a heterogeneous cell population expanded in cancer, infection and autoimmunity capable of suppressing T-cell functions. Checkpoint inhibitors have emerged as a key therapeutic strategy in immune-oncology. While checkpoint molecules were initially associated with T cell functions, recent evidence suggests a broader expression and function in innate myeloid cells. Previous studies provided first evidence for a potential role for checkpoints on MDSCs, yet the human relevance remained poorly understood. Therefore, we investigated the expression and functional relevance of checkpoint molecules in human MDSC-T-cell interactions. Our studies demonstrate that programmed death-ligand 1 (PD-L1) is expressed on granulocytic MDSCs upon co-culture with T cells. Transwell experiments showed that cell-to-cell contact was required for MDSC-T-cell interactions and antibody blocking studies showed that targeting PD-L1 partially impaired MDSC-mediated T-cell suppression. Collectively, these studies suggest a role for PD-L1 in human MDSC function and thereby expand the functionality of this checkpoint beyond T cells, which could pave the way for further understanding and therapeutic targeting of PD-1/PD-L1 in innate immune-mediated diseases.
Copyright © 2017 European Federation of Immunological Societies. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Checkpoints; MDSC; Myeloid-derived suppressor cells; PD-1; PD-L1; T-cell suppression

Mesh:

Substances:

Year:  2017        PMID: 28987474     DOI: 10.1016/j.imlet.2017.10.001

Source DB:  PubMed          Journal:  Immunol Lett        ISSN: 0165-2478            Impact factor:   3.685


  34 in total

1.  SET/PP2A signaling regulates macrophage positioning in hypoxic tumor regions by amplifying chemotactic responses.

Authors:  Shaolong Zhang; Jingping Zhou; Pengzhao Shang; Guomeng Zhao; Anlei Wang; Jinlei Mao; Yuhang Tao; Ziyi Chen; Xuehao Wang; Changying Guo
Journal:  Exp Mol Med       Date:  2022-10-12       Impact factor: 12.153

Review 2.  Myeloid-driven mechanisms as barriers to antitumor CD8+ T cell activity.

Authors:  Sean H Colligan; Stephanie L Tzetzo; Scott I Abrams
Journal:  Mol Immunol       Date:  2019-12-26       Impact factor: 4.407

Review 3.  Resistance to Immune Checkpoint Inhibitors Secondary to Myeloid-Derived Suppressor Cells: A New Therapeutic Targeting of Haematological Malignancies.

Authors:  Alejandro Olivares-Hernández; Luis Figuero-Pérez; Eduardo Terán-Brage; Álvaro López-Gutiérrez; Álvaro Tamayo Velasco; Rogelio González Sarmiento; Juan Jesús Cruz-Hernández; José Pablo Miramontes-González
Journal:  J Clin Med       Date:  2021-04-28       Impact factor: 4.241

4.  Targeting tumor-derived NLRP3 reduces melanoma progression by limiting MDSCs expansion.

Authors:  Isak W Tengesdal; Dinoop R Menon; Douglas G Osborne; Charles P Neff; Nicholas E Powers; Fabia Gamboni; Adolfo G Mauro; Angelo D'Alessandro; Davide Stefanoni; Morkos A Henen; Taylor S Mills; Dennis M De Graaf; Tania Azam; Beat Vogeli; Brent E Palmer; Eric M Pietras; James DeGregori; Aik-Choon Tan; Leo A B Joosten; Mayumi Fujita; Charles A Dinarello; Carlo Marchetti
Journal:  Proc Natl Acad Sci U S A       Date:  2021-03-09       Impact factor: 11.205

Review 5.  Hijacked Immune Cells in the Tumor Microenvironment: Molecular Mechanisms of Immunosuppression and Cues to Improve T Cell-Based Immunotherapy of Solid Tumors.

Authors:  Emre Balta; Guido H Wabnitz; Yvonne Samstag
Journal:  Int J Mol Sci       Date:  2021-05-27       Impact factor: 5.923

6.  Cancer-specific immune evasion and substantial heterogeneity within cancer types provide evidence for personalized immunotherapy.

Authors:  Martin Thelen; Kerstin Wennhold; Jonas Lehmann; Maria Garcia-Marquez; Sebastian Klein; Elena Kochen; Philipp Lohneis; Axel Lechner; Svenja Wagener-Ryczek; Patrick Sven Plum; Oscar Velazquez Camacho; David Pfister; Fabian Dörr; Matthias Heldwein; Khosro Hekmat; Dirk Beutner; Jens Peter Klussmann; Fabinshy Thangarajah; Dominik Ratiu; Wolfram Malter; Sabine Merkelbach-Bruse; Christiane Josephine Bruns; Alexander Quaas; Michael von Bergwelt-Baildon; Hans A Schlößer
Journal:  NPJ Precis Oncol       Date:  2021-06-16

7.  Bispecific Antibody Armed Metabolically Enhanced Headless CAR T Cells.

Authors:  Archana Thakur; John Scholler; Ewa Kubicka; Edwin T Bliemeister; Dana L Schalk; Carl H June; Lawrence G Lum
Journal:  Front Immunol       Date:  2021-07-05       Impact factor: 7.561

8.  Emergency myelopoiesis contributes to immune cell exhaustion and pulmonary vascular remodelling.

Authors:  Chunhua Fu; Yuanqing Lu; Mason A Williams; Mark L Brantly; Corey E Ventetuolo; Laurence M Morel; Borna Mehrad; Edward W Scott; Andrew J Bryant
Journal:  Br J Pharmacol       Date:  2020-02-04       Impact factor: 9.473

Review 9.  Obesity-Associated Myeloid Immunosuppressive Cells, Key Players in Cancer Risk and Response to Immunotherapy.

Authors:  Maria Dulfary Sanchez-Pino; Linda Anne Gilmore; Augusto C Ochoa; Justin C Brown
Journal:  Obesity (Silver Spring)       Date:  2021-02-22       Impact factor: 9.298

Review 10.  Immunosuppressive Role of Myeloid-Derived Suppressor Cells and Therapeutic Targeting in Lung Cancer.

Authors:  Jie Ma; Huaxi Xu; Shengjun Wang
Journal:  J Immunol Res       Date:  2018-03-25       Impact factor: 4.818

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.